EA201500301A1 - Содержащая носитель кислорода на основе гемоглобина фармацевтическая композиция для адресного лечения рака и предотвращения рецидивов рака - Google Patents
Содержащая носитель кислорода на основе гемоглобина фармацевтическая композиция для адресного лечения рака и предотвращения рецидивов ракаInfo
- Publication number
- EA201500301A1 EA201500301A1 EA201500301A EA201500301A EA201500301A1 EA 201500301 A1 EA201500301 A1 EA 201500301A1 EA 201500301 A EA201500301 A EA 201500301A EA 201500301 A EA201500301 A EA 201500301A EA 201500301 A1 EA201500301 A1 EA 201500301A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- hemoglobin
- oxygen carrier
- pharmaceutical composition
- based oxygen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 9
- 201000011510 cancer Diseases 0.000 title abstract 7
- 102000001554 Hemoglobins Human genes 0.000 title abstract 5
- 108010054147 Hemoglobins Proteins 0.000 title abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract 5
- 229910052760 oxygen Inorganic materials 0.000 title abstract 5
- 239000001301 oxygen Substances 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title 1
- 230000000306 recurrent effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 210000005102 tumor initiating cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712853P | 2012-10-12 | 2012-10-12 | |
| US13/713,031 US20140106004A1 (en) | 2012-10-12 | 2012-12-13 | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| PCT/US2013/064418 WO2014059199A1 (en) | 2012-10-12 | 2013-10-11 | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201500301A1 true EA201500301A1 (ru) | 2015-08-31 |
Family
ID=50475529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201500301A EA201500301A1 (ru) | 2012-10-12 | 2013-10-11 | Содержащая носитель кислорода на основе гемоглобина фармацевтическая композиция для адресного лечения рака и предотвращения рецидивов рака |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20140106004A1 (https=) |
| EP (1) | EP2906222A4 (https=) |
| JP (1) | JP6113850B2 (https=) |
| KR (1) | KR20150065881A (https=) |
| CN (1) | CN104717966B (https=) |
| AP (1) | AP2015008315A0 (https=) |
| AR (1) | AR093023A1 (https=) |
| AU (1) | AU2013329121B2 (https=) |
| BR (1) | BR112015007475A2 (https=) |
| CA (1) | CA2884521C (https=) |
| CL (1) | CL2015000897A1 (https=) |
| EA (1) | EA201500301A1 (https=) |
| IL (1) | IL237763A (https=) |
| MA (1) | MA37994A2 (https=) |
| MX (1) | MX367562B (https=) |
| PH (1) | PH12015500562B1 (https=) |
| SG (3) | SG10201608747RA (https=) |
| TW (1) | TW201414489A (https=) |
| UY (1) | UY35082A (https=) |
| WO (1) | WO2014059199A1 (https=) |
| ZA (1) | ZA201501949B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9636404B2 (en) * | 2013-05-13 | 2017-05-02 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| CN106536056B (zh) | 2014-06-13 | 2021-07-16 | 儿童医学中心公司 | 分离线粒体的产品和方法 |
| US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
| US11903974B2 (en) | 2015-11-30 | 2024-02-20 | Flagship Pioneering Innovations V, Inc. | Methods and compositions relating to chondrisomes from cultured cells |
| WO2017124037A1 (en) * | 2016-01-15 | 2017-07-20 | The Children's Medical Center Corporation | Therapeutic use of mitochondria and combined mitochondrial agents |
| CA3028589A1 (en) * | 2016-06-21 | 2017-12-28 | Therapure Biopharma Inc. | Hemoglobin-targeted drug delivery for the treatment of cancer |
| US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
| EP3612177A4 (en) | 2017-04-21 | 2021-01-13 | Lunella Biotech, Inc. | TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY |
| CA3063450A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| PH12019502594A1 (en) | 2017-05-19 | 2020-10-26 | Lunella Biotech Inc | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| KR102854338B1 (ko) | 2017-06-26 | 2025-09-03 | 루넬라 바이오테크 인코포레이티드 | 미토케토신: 암 세포에서 케톤 대사를 표적화하는 미토콘드리아-기반의 치료제 |
| JPWO2019124423A1 (ja) * | 2017-12-19 | 2020-10-22 | 国立大学法人 岡山大学 | がんの進行抑制、治療、予防及び／又は再発予防剤 |
| CN111558032B (zh) * | 2020-05-19 | 2023-08-22 | 中国科学院宁波材料技术与工程研究所 | 一种蛋白纳米药物及其制备方法与应用 |
| CN114344263B (zh) * | 2022-02-21 | 2023-08-01 | 杭州普略生物科技有限公司 | 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用 |
| KR102793996B1 (ko) | 2022-03-31 | 2025-04-09 | 충남대학교산학협력단 | 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물 |
| WO2025222059A1 (en) * | 2024-04-17 | 2025-10-23 | Prolong Pharmaceuticals Llc | Method of treating cancer using pegylated bovine hemoglobin |
| CN119746044A (zh) * | 2025-03-06 | 2025-04-04 | 润方（北京）生物医药研究院有限公司 | 血红蛋白氧载体在制备抗病毒药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478806A (en) * | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
| CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
| US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| JP2006508939A (ja) * | 2002-10-29 | 2006-03-16 | エンジーン， インコーポレイテッド | 癌処置のための組成物 |
| EP2389068A4 (en) * | 2009-01-23 | 2012-07-18 | Cancer Rec Tech Ltd | HEMGE OF THE HEDGEHOG SIGNAL PATH |
| NO2440239T3 (https=) * | 2009-06-09 | 2018-02-10 | ||
| EP2451459B1 (en) * | 2009-07-07 | 2017-11-22 | Normoxys, Inc. | Method of reducing multi-drug resistance using inositol tripyrophosphate |
| US8808748B2 (en) * | 2010-04-20 | 2014-08-19 | Vindico NanoBio Technology Inc. | Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same |
| US7989593B1 (en) * | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US20110319332A1 (en) * | 2010-06-23 | 2011-12-29 | Bing Lou Wong | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US8048856B1 (en) * | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US7932356B1 (en) * | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
-
2012
- 2012-12-13 US US13/713,031 patent/US20140106004A1/en not_active Abandoned
-
2013
- 2013-10-11 AP AP2015008315A patent/AP2015008315A0/xx unknown
- 2013-10-11 BR BR112015007475A patent/BR112015007475A2/pt not_active IP Right Cessation
- 2013-10-11 SG SG10201608747RA patent/SG10201608747RA/en unknown
- 2013-10-11 SG SG11201502133SA patent/SG11201502133SA/en unknown
- 2013-10-11 SG SG10201607846PA patent/SG10201607846PA/en unknown
- 2013-10-11 MA MA37994A patent/MA37994A2/fr unknown
- 2013-10-11 EA EA201500301A patent/EA201500301A1/ru unknown
- 2013-10-11 CA CA2884521A patent/CA2884521C/en active Active
- 2013-10-11 KR KR1020157012185A patent/KR20150065881A/ko not_active Ceased
- 2013-10-11 WO PCT/US2013/064418 patent/WO2014059199A1/en not_active Ceased
- 2013-10-11 EP EP13844670.3A patent/EP2906222A4/en not_active Ceased
- 2013-10-11 CN CN201380053346.1A patent/CN104717966B/zh not_active Expired - Fee Related
- 2013-10-11 MX MX2015004512A patent/MX367562B/es active IP Right Grant
- 2013-10-11 AU AU2013329121A patent/AU2013329121B2/en not_active Ceased
- 2013-10-11 JP JP2015536905A patent/JP6113850B2/ja not_active Expired - Fee Related
- 2013-10-14 UY UY35082A patent/UY35082A/es not_active Application Discontinuation
- 2013-10-14 TW TW102136951A patent/TW201414489A/zh unknown
- 2013-10-15 AR ARP130103741A patent/AR093023A1/es unknown
-
2014
- 2014-06-19 US US14/308,725 patent/US9056098B2/en active Active
-
2015
- 2015-03-16 PH PH12015500562A patent/PH12015500562B1/en unknown
- 2015-03-16 IL IL237763A patent/IL237763A/en active IP Right Grant
- 2015-03-20 ZA ZA2015/01949A patent/ZA201501949B/en unknown
- 2015-04-09 CL CL2015000897A patent/CL2015000897A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201500301A1 (ru) | Содержащая носитель кислорода на основе гемоглобина фармацевтическая композиция для адресного лечения рака и предотвращения рецидивов рака | |
| PH12015502536A1 (en) | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging | |
| JOP20180104B1 (ar) | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس | |
| MX2016006119A (es) | Derivados de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-fluoro-4-[( 3-oxo-4h-pirido[2,3 b]piracin-8-il)oxi]fenil]urea como inhibidores de raf para el tratamiento del cancer. | |
| BR112015016681A2 (pt) | métodos de tratamento de câncer pancreático | |
| MX377405B (es) | Compuestos para el tratamiento de cáncer. | |
| AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
| CL2007002994A1 (es) | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. | |
| MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer | |
| CR11687A (es) | Terapia de combinación de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| PH12014500248B1 (en) | Treatment of breast cancer | |
| WO2013093508A3 (en) | Wnt pathway inhibitors | |
| EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
| WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
| MX2010009782A (es) | Tratamientos antitumorales mejorados. | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| CL2014002181A1 (es) | Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma. | |
| MX2015003343A (es) | Tratamiento combinado con el farmaco de interferencia de netrina-1 y el farmaco quimioterapeutico. | |
| EA201391131A1 (ru) | Сочетания с мацитентаном для лечения полиморфной глиобластомы | |
| WO2012138691A3 (en) | Diagnosis and treatment of taxane-resistant cancers | |
| MY186484A (en) | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence | |
| MX2019003374A (es) | Composicion combinada para prevenir o tratar cancer que comprende un derivado de benzofenona tiazol como un vda e inhibidor de topoisomerasa. | |
| CL2011001316A1 (es) | Uso de una combinacion que comprende ave8062 o una sal del mismo y docetaxel para preparar un medicamento util en el tratamiento de tumores solidos. |